361 related articles for article (PubMed ID: 34869014)
1. Cancer-Immunity Cycle and Therapeutic Interventions- Opportunities for Including Pet Dogs With Cancer.
Von Rueden SK; Fan TM
Front Oncol; 2021; 11():773420. PubMed ID: 34869014
[TBL] [Abstract][Full Text] [Related]
2. Comparative Immunology and Immunotherapy of Canine Osteosarcoma.
Mason NJ
Adv Exp Med Biol; 2020; 1258():199-221. PubMed ID: 32767244
[TBL] [Abstract][Full Text] [Related]
3. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
Shaver KA; Croom-Perez TJ; Copik AJ
Front Immunol; 2021; 12():679117. PubMed ID: 33995422
[TBL] [Abstract][Full Text] [Related]
4. Toward integrative cancer immunotherapy: targeting the tumor microenvironment.
Emens LA; Silverstein SC; Khleif S; Marincola FM; Galon J
J Transl Med; 2012 Apr; 10():70. PubMed ID: 22490302
[TBL] [Abstract][Full Text] [Related]
5. Immuno-oncology-101: overview of major concepts and translational perspectives.
Allard B; Aspeslagh S; Garaud S; Dupont FA; Solinas C; Kok M; Routy B; Sotiriou C; Stagg J; Buisseret L
Semin Cancer Biol; 2018 Oct; 52(Pt 2):1-11. PubMed ID: 29428479
[TBL] [Abstract][Full Text] [Related]
6. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
7. Evolution of animal models in cancer vaccine development.
Wei WZ; Jones RF; Juhasz C; Gibson H; Veenstra J
Vaccine; 2015 Dec; 33(51):7401-7407. PubMed ID: 26241945
[TBL] [Abstract][Full Text] [Related]
8. Symphony of nanomaterials and immunotherapy based on the cancer-immunity cycle.
Li Q; Shi Z; Zhang F; Zeng W; Zhu D; Mei L
Acta Pharm Sin B; 2022 Jan; 12(1):107-134. PubMed ID: 35127375
[TBL] [Abstract][Full Text] [Related]
9. Of Mice, Dogs, Pigs, and Men: Choosing the Appropriate Model for Immuno-Oncology Research.
Overgaard NH; Fan TM; Schachtschneider KM; Principe DR; Schook LB; Jungersen G
ILAR J; 2018 Dec; 59(3):247-262. PubMed ID: 30476148
[TBL] [Abstract][Full Text] [Related]
10. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.
Finn OJ
Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii6-9. PubMed ID: 22918931
[TBL] [Abstract][Full Text] [Related]
11. Cancer Epigenetics, Tumor Immunity, and Immunotherapy.
Cao J; Yan Q
Trends Cancer; 2020 Jul; 6(7):580-592. PubMed ID: 32610068
[TBL] [Abstract][Full Text] [Related]
12. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
13. Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy.
Yang J; Zhang C
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1612. PubMed ID: 32114718
[TBL] [Abstract][Full Text] [Related]
14. A Role for Dogs in Advancing Cancer Immunotherapy Research.
Dow S
Front Immunol; 2019; 10():2935. PubMed ID: 32010120
[TBL] [Abstract][Full Text] [Related]
15. Cancer-associated fibroblasts: Key players in shaping the tumor immune microenvironment.
Desbois M; Wang Y
Immunol Rev; 2021 Jul; 302(1):241-258. PubMed ID: 34075584
[TBL] [Abstract][Full Text] [Related]
16. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium.
Curigliano G; Criscitiello C; Esposito A; Fumagalli L; Gelao L; Locatelli M; Minchella I; Goldhirsch A
Breast; 2013 Aug; 22 Suppl 2():S96-9. PubMed ID: 24074802
[TBL] [Abstract][Full Text] [Related]
17. Innate and Adaptive Immune Cell Metabolism in Tumor Microenvironment.
Wu D
Adv Exp Med Biol; 2017; 1011():211-223. PubMed ID: 28875492
[TBL] [Abstract][Full Text] [Related]
18. Mechanical Immunoengineering of T cells for Therapeutic Applications.
Lei K; Kurum A; Tang L
Acc Chem Res; 2020 Dec; 53(12):2777-2790. PubMed ID: 33258577
[TBL] [Abstract][Full Text] [Related]
19. High-dimensional immune-profiling in cancer: implications for immunotherapy.
Chuah S; Chew V
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32034066
[TBL] [Abstract][Full Text] [Related]
20. Prostaglandin E Receptor 4 Antagonist in Cancer Immunotherapy: Mechanisms of Action.
Take Y; Koizumi S; Nagahisa A
Front Immunol; 2020; 11():324. PubMed ID: 32210957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
